IKZF1 and systemic lupus erythematosus: These results consolidate previous data on B cells activated with CD40L and BAFF,27 providing further insights into the relevance of targeting Ikaros and Aiolos in patients with SLE because of the ability to inhibit TLR7 mediated B cell differentiation.